Skip to main content
Fig. 3 | Renal Replacement Therapy

Fig. 3

From: Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis

Fig. 3

Plasma concentrations of topiroxostat and its metabolites after repeated administration of 20 mg twice per day of topiroxostat. There were no significant differences between the concentrations of topiroxostat and its three metabolites at weeks 4, 12, 26, and 52 (paired t test vs. 4 weeks, after Bonferroni corrections). (n = 20, week 4; n = 19, weeks 19, 26, and 52). Mean ± SD

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us